GENSCRIPT BIO(HK:01548) HTSC·2025-11-13 13:06Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 21.55 [7][5] Core Insights - The company has shown a significant reduction in losses, with a net loss of USD 266 million in the first three quarters of 2025, down from USD 1.25 billion in Q3 2024 [1] - CARVYKTI's sales are on a strong upward trend, with Q3 sales reaching USD 524 million, representing a 19% quarter-over-quarter increase and an 83% year-over-year increase [2][3] - The company aims to achieve USD 3 billion in revenue by 2035, with various business segments expected to grow at different rates [4] Summary by Sections Financial Performance - For the first three quarters of 2025, CARVYKTI generated sales of USD 1.332 billion, a 112% year-over-year increase, with Q3 sales alone at USD 524 million [1] - The company forecasts revenues of USD 973 million, USD 806 million, and USD 933 million for 2025, 2026, and 2027 respectively, with corresponding net profits of USD 11 million, USD 66 million, and USD 355 million [5][10] Business Growth and Strategy - The company is expanding its treatment indications with ongoing Phase III clinical trials for CARTITUDE-5 and CARTITUDE-6 [3] - The production capacity is expected to reach 10,000 cases annually by the end of 2025, with new facilities in Belgium and the U.S. coming online [3] Valuation and Market Position - The estimated market value of the company is HKD 470.93 billion, with a breakdown of HKD 259.49 billion for ongoing operations and HKD 211.45 billion for the equity in its joint venture [13][15] - The report highlights a price-to-sales (PS) ratio of 4.14x for 2026, reflecting a 20% discount to comparable companies [13]